Therapeutic Effects of Highly Purified De-Glycosylated Gcmaf in the Immunotherapy of Patients With Chronic Diseases

Abstract

The de-Glycosylated vitamin D binding protein is a powerful Macrophage Activating Factor (GcMAF) that shows multiple biological effects that could be exploited in the immunotherapy of tumours, viral infections and autism. Here we report the observation of a series of clinical cases describing the results obtained administering highly purified GcMAF to patients with diverse types of chronic diseases. These are heterogeneous and refer to patients with different types of diseases at different stages. In some cases, patients underwent other complementary treatments such as stem cell infusion or administration of supplements. In patients harbouring tumours, GcMAF treatment was initiated at late stages of tumour progression. Therefore, since this is an open-label, non-controlled, retrospective analysis, caution must be employed when ascribing cause and effect to any treatment outcome. However, the response to GcMAF was robust and certain trends emerge evident. In all cases (n = 7), GcMAF subcutaneous injections were associated with improvement of clinical conditions. No adverse side effects were reported. The observation reported here confirm and extend the results previously presented by several Authors and open the way to further trials aimed at assessing the precise role and indications for GcMAF in the immunotherapy of chronic diseases.

Effects of Gc-Macrophage Activating Factor in Human Neurons; Implications for Treatment of Chronic Fatigue Syndrome

“…Recent evidence, however, suggests that the therapeutic results observed with GcMAF are due not only to macrophage activation, but also to other direct effects of GcMAF on cell signalling and metabolism. We recently proposed that these effects may be explained considering the interconnection between GcMAF and VDR signalling pathways (Thyer et al, 2013b). The results presented in this study suggest a further interconnection with other signalling pathways that include ERK and NF-κB.…”

“…These range from inhibition of angiogenesis (Pacini et al, 2011) to direct inhibition of human cancer cell proliferation and metastatic potential (Gregory et al, 2010;Pacini et al, 2012b) to increased production of energy at the mitochondrial level (Pacini et al, 2013). We recently demonstrated that these multifaceted effects of GcMAF can be interpreted considering the interconnection between the GcMAF and the Vitamin D Receptor (VDR) signalling pathways (Thyer et al, 2013b).…”

“…In fact, these cells represent a model system to study the neurobiology of neurodegenerative diseases (Xie et al, 2010) and they are used to evaluate the neuroprotective effects of a variety of substances (Thapa et al, 2013). In addition, these cells express the VDR receptor, thus making them suitable to study those effects of GcMAF that Science Publications AJI are interconnected with VDR receptor signalling (Celli et al, 1999;Thyer et al, 2013b). Figure 2, shows that GcMAF (8-800 pM) significantly increased neuronal cell viability and metabolic activity in a dose-dependent manner, with significant effects observed even at the lowest pM concentration.…”

Clinical Experience of Cancer Immunotherapy Integrated With Oleic Acid Complexed With De-Glycosylated Vitamin D Binding Protein

“…To our knowledge, this is the first example of actual images of tumor volume reduction following GcMAF immunotherapy. In effect, so far the effectiveness of immunotherapy of cancer with GcMAF has relied upon non-specific markers such as serum α-Nacetylgalactosaminidase levels (Yamamoto et al, 2008a;2008b;2008c;Thyer et al, 2013a) or anecdotic reports (Inui et al, 2013;Thyer et al, 2013b).…”

“…The potent immunotherapeutic effects of GcMAF in human tumors have been demonstrated since 2007 in a variety of cancers ranging from the most common breast and prostate cancers to the less frequent oligodendroglioma (Yamamoto et al, 2008a;2008b;2008c;Inui et al, 2013;Thyer et al, 2013a;2013b).…”